A growth-oriented biopharmaceutical company improving patient lives by developing and commercializing advanced products across a range of therapies.

Addressing today’s medical challenges with a diversified portfolio of innovative products and partnerships.

products

We believe that our products have the potential to impact people's lives.

product pipeline

Xeris has developed a robust pipeline of development programs for extending currently marketed products into important new indications and uses. Our pipeline also launches new products utilizing our proprietary formulation technology platforms to support long-term product development and commercial success.

Pipeline includes products across the range of development

Product Candidate
Indication
Pre-Clinical
Phase 1
Phase 2
Phase 3
Marketed
Gvoke® (US) (glucagon injection)
Severe Hypoglycemia info
 
PreClinical
 
Phase 1
 
Phase 2
 
Phase 3
 
Marketed

Severe hypoglycemia, or severe low blood sugar, occurs when your blood sugar gets so low that you need help to bring it back up. Sometimes people with very low blood sugar may have a hard time thinking straight or controlling their body, get very tired, refuse to eat, pass out, or even have a seizure. It is an emergency situation that needs to be treated immediately.*

*National Institute of Diabetes and Digestive and Kidney Diseases. Hypoglycemia. https://www.niddk.nih.gov/-/media/Files/Diabetes/hypoglycemia_508.pdf. Published July 2021.

Keveyis® (dichlorphenamide)
Primary Periodic Paralysis†
 
PreClinical
 
Phase 1
 
Phase 2
 
Phase 3
 
Marketed

Primary Periodic Paralysis (PPP) is a rare genetic condition that affects muscles and causes episodes of muscle weakness and/or temporary paralysis, that can be progressive and debilitating. 1,2

1 Statland JM, Fontaine B, Hanna MG, et al. Review of the diagnosis and treatment of periodic paralysis. Muscle Nerve. 2018;57:522-530.
2 Cavel-Greant D, Lehmann-Horn F, Jurkat-Rott K. The impact of permanent muscle weakness on quality of life in periodic paralysis: a survey of 66 patients. Acta Myol. 2012;31:126-133.

Ogluo® (EU)** (glucagon)
Severe Hypoglycemia
 
PreClinical
 
Phase 1
 
Phase 2
 
Phase 3
 
Marketed

Severe hypoglycemia, or severe low blood sugar, occurs when your blood sugar gets so low that you need help to bring it back up. Sometimes people with very low blood sugar may have a hard time thinking straight or controlling their body, get very tired, refuse to eat, pass out, or even have a seizure. It is an emergency situation that needs to be treated immediately. *

*National Institute of Diabetes and Digestive and Kidney Diseases. Hypoglycemia. https://www.niddk.nih.gov/-/media/Files/Diabetes/hypoglycemia_508.pdf. Published July 2021.

Recorlev® (levoketoconazole)
Endogenous Cushing's Syndrome†
 
PreClinical
 
Phase 1
 
Phase 2
 
Phase 3
 
Marketed

Endogenous CS is a rare, serious endocrine disorder caused by chronic exposure to elevated levels of cortisol; left untreated, it can be fatal. Often the result of a benign tumor of the pituitary gland that tells the body to overproduce high levels of cortisol for a sustained period of time. CS results in physical and emotional signs and symptoms that are debilitating for those living with CS. It is most common among adults aged 30 to 50 years and is more prevalent in females, accounting for 70% of cases.*

* The National Institute of Diabetes and Digestive and Kidney Diseases Health Information Center. Cushing’s Syndrome. Accessed Sept. 14, 2020. https://www.niddk.nih.gov/health-information/endocrine-diseases/cushings-syndrome.

Self-Administered Glucagon for Prevention
Exercise-Associated Hypoglycemia
 
PreClinical
 
Phase 1
 
Phase 2
 
Phase 3
 
Marketed

Exercise-Associated Hypoglycemia is characterized by a sudden and exaggerated spike in insulin and drop in blood sugar levels. The condition is triggered by vigorous exercise. Signs and symptoms include fainting (syncope),1 shakiness, nervousness, sweating, dizziness or light-headedness, sleepiness, confusion, difficulty speaking, anxiety, and weakness.2

1. Hyperinsulinemic hypoglycemia, familial, 7; HHF7. OMIM. November 2008; http://omim.org/entry/610021. Accessed 12/4/2013.
2. Hypoglycemia. NIDDK. November 6, 2012; http://diabetes.niddk.nih.gov/dm/pubs/hypoglycemia/#symptoms. Accessed 12/4/2013.

Levothyroxine
Endocrinology: Hypothyroidism
 
PreClinical
 
Phase 1
 
Phase 2
 
Phase 3
 
Marketed

Hypothyroidism, also known as underactive thyroid disease, is a condition in which the thyroid gland does not create and release enough thyroid hormone into the bloodstream. Hypothyroidism may not cause noticeable symptoms in the early stages. Over time, untreated hypothyroidism can cause a number of health problems, such as obesity, joint pain, infertility, and heart disease. Hypothyroidism is a fairly common condition that can affect people of all ages, genders, and ethnicities.

XP-9164
Gastroenterology
 
PreClinical
 
Phase 1
 
Phase 2
 
Phase 3
 
Marketed

Gastroenterology is a branch of medicine concerned with digestive diseases. The practice of gastroenterology concentrates on the diagnosis and treatment of diseases involving the esophagus, stomach, small intestine and large intestine (colon), liver, gallbladder, and pancreas.

† Orphan Drug Designation
*Fast Track Designation
**Xeris has an exclusive agreement with Tetris Pharma Limited, a subsidiary of Arecor Therapeutics plc, for the commercialization of Ogluo® in the European Economic Area, United Kingdom, and Switzerland

our values

Focus on Patients

We are committed to providing patients with therapies that improve the patient experience.

Empowered and Accountable

We make informed decisions to meet goals and commitments; and work together to help each other achieve those goals.

Do the Right Thing

We act with integrity in our work, in the relationships we build, and in how we develop our products.

Innovation

We find ways to bring unique and effective solutions to therapeutic areas with patient need.

our mission

Solutions for many therapeutic areas

We're currently developing innovative, ready-to-use solutions for various therapeutic categories to remove many associated treatment burdens and ultimately improve patients' lives.

leadership

We’re people people.

We’ve handpicked our team to ensure each individual’s strengths further the pursuit of our shared goal to change patients’ lives.